Zinacef

Cefuroxime Na

Treatment of infections in adults & childn including neonates (from birth): Community acquired pneumonia; acute exacerbations of chronic bronchitis; complicated UTIs, including pyelonephritis; soft-tissue infections (cellulitis, erysipelas, wound infections); intra-abdominal infections. Prophylaxis against infection in GI (including oesophageal), orthopaedic, CV, gynaecological surgery (including caesarean section).

Adult & childn ≥40 kg Community acquired pneumonia & acute exacerbations of chronic bronchitis, soft-tissue & intra-abdominal infections 750 mg every 8 hr IV or IM. Complicated UTIs 1.5 g every 8 hr IV or IM. Severe infections 750 mg every 6 hr IV, or 1.5 g every 8 hr IV. Surgical prophylaxis for GI, gynaecological surgery, orthopaedic operations 1.5 g w/ induction of anaesth. May be supplemented w/ two 750 mg doses IM after 8 & 16 hr. Surgical prophylaxis for CV & oesophageal operations 1.5 g w/ induction of anaesth followed by 750 mg IM every 8 hr for a further 24 hr. Infants & toddlers >3 wk & childn <40 kg Community acquired pneumonia, complicated UTIs, soft-tissue & intra-abdominal infections 30-100 mg/kg/day IV given as 3 or 4 divided doses; 60 mg/kg/day is appropriate for most infections. Infants (birth to 3 wk) Community acquired pneumonia, complicated UTIs, soft-tissue & intra-abdominal infections 30-100 mg/kg/day IV given as 2-3 divided doses. Renal impairment >20 mL/min/1.73 m² 750 mg to 1.5 g tds, CrCl 10-20 mL/min/1.73 m² 750 mg bd, CrCl <10 mL/min/1.73 m² 750 mg once daily. Patients on haemodialysis A further 750 mg dose should be given IV or IM at the end of each dialysis. Cefuroxime Na can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 L of dialysis fluid. Renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units 750 mg bd.

Hypersensitivity to cefuroxime or to other cephalosporins. History of severe hypersensitivity to any other type of β-lactam antibacterial agents (penicillins, monobactams, carbapenems).

Patients w/ history of non-severe hypersensitivity to other β-lactam agents. Immediately discontinue in case of severe hypersensitivity reactions. Overgrowth of Candida. Prolonged use may result in overgrowth of other non-susceptible organisms (eg, Enterococci, Clostridium difficile). Antibacterial agent-associated pseudomembranous colitis. Not for intracameral use. Concurrent treatment w/ potent diuretics eg, frusemide or aminoglycosides. Monitor renal function in elderly & patients w/ pre-existing renal impairment. Not suitable for treating gm -ve non-fermenting bacterial infections. +ve Coombs' test. Slight interference may be observed w/ Cu reduction methods (Benedict's, Fehling's, Clinitest). False -ve in the ferricyanide test. Pregnancy & lactation.

Neutropenia, eosinophilia, decreased Hb conc; transient rise in liver enzymes; inj site reactions eg, pain & thrombophlebitis.

May affect gut flora, leading to lower oestrogen reabsorption & reduced combined OC efficacy. Prolonged excretion & elevated peak serum level w/ probenecid. Increased risk of renal impairment w/ strong-acting diuretics (eg, frusemide) or nephrotoxic prep (eg, aminoglycosides). Increased INR w/ oral anticoagulants.

Cephalosporins

J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.

A